Sugi Predict

Sugi Predict / Compounds / SCHEMBL9989119

SCHEMBL9989119

SCHEMBL9989119

Cc1cc(Br)cnc1S(C)(=O)=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ NPC1 O15118 1/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ EDNRA P25101 1/20 0.35
▸ S1PR1 P21453 1/20 0.35
▸ S1PR3 Q99500 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ BRD4 O60885 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ PTGDR2 Q9Y5Y4 1/20 0.32
▸ AURKA O14965 1/20 0.32
▸ DAPK3 O43293 1/20 0.32
▸ JAK2 O60674 1/20 0.32
▸ PRKD3 O94806 1/20 0.32
▸ MAP4K4 O95819 1/20 0.32
▸ PAK4 O96013 1/20 0.32
▸ ABL1 P00519 1/20 0.32
▸ NTRK1 P04629 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1464993 0.82 S1PR1 (0.37) KMT2AMEN1NPC1ALDH1A1EDNRA
SCHEMBL15047723 0.79 NOS3 (0.45) KMT2AMEN1ALDH1A1KDM4EPTGS2
SCHEMBL15052416 0.78 APLNR (0.36) KMT2AMEN1NPC1ALDH1A1HSD17B10
SCHEMBL15053325 0.78 GLP1R (0.40) KMT2AMEN1HSD17B10L3MBTL1POLB
SCHEMBL15109982 0.78 ENPP2 (0.35) ALDH1A1MAP4K4FYNRETKDR
SCHEMBL2172509 0.78 S100A9 (0.36) ALDH1A1BRD4MAP4K4FYNRET
SCHEMBL7511857 0.76 LMNA (0.41) KMT2AMEN1HSD17B10HTTL3MBTL1
SCHEMBL15052606 0.76 SHMT2 (0.41) KMT2AMEN1SMN1; SMN2HTTPOLB
SCHEMBL15052794 0.76 NPC1 (0.34) KMT2AMEN1NPC1ALDH1A1HSD17B10
SCHEMBL15053192 0.76 EDNRA (0.39) KMT2ANPC1ALDH1A1EDNRAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240216378-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2024-07-04 — — US disclosed
US-20240216378-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2024-07-04 — — US disclosed
US-20240216378-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2024-07-04 — — US disclosed
US-11931363-B2 Triazolopyrimidine compounds and uses thereof NOVARTIS AG (CH) 2024-03-19 — — US disclosed
US-20230033320-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH (CN) 2023-02-02 — — US disclosed
US-11207325-B2 Triazolopyrimidine compounds and uses thereof NOVARTIS AG (CH) 2021-12-28 — — US disclosed
US-20200323859-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) 2020-10-15 — — US disclosed
US-10676479-B2 Imidazolepyridine compounds and uses thereof NOVARTIS AG (CH) 2020-06-09 — — US disclosed
US-20190233426-A1 IMIDAZOLEPYRIDINE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2019-08-01 — — US disclosed
US-20190142837-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2019-05-16 — — US disclosed
US-20130244993-A1 SUBSTITUTED 5-,6- AND 7-MEMBERED HETEROCYCLES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, AND THEIR USE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-09-19 — — US disclosed
WO-2013093849-A1 DIHYDRO-BENZO-OXAZINE AND DIHYDRO-PYRIDO-OXAZINE DERIVATIVES NOVARTIS AG (CH) 2013-06-27 — — WO disclosed
WO-2013093850-A1 QUINOLINE DERIVATIVES NOVARTIS AG (CH) 2013-06-27 — — WO disclosed
WO-2013093850-A1 QUINOLINE DERIVATIVES NOVARTIS AG (CH) 2013-06-27 — — WO disclosed
WO-2013093849-A1 DIHYDRO-BENZO-OXAZINE AND DIHYDRO-PYRIDO-OXAZINE DERIVATIVES NOVARTIS AG (CH) 2013-06-27 — — WO disclosed
US-20130165436-A1 Dihydro-Benzo-Oxazine and Dihydro-Pyrido-Oxazine Derivatives NOVARTIS AG (CH) 2013-06-27 — — US disclosed
US-20130165436-A1 Dihydro-Benzo-Oxazine and Dihydro-Pyrido-Oxazine Derivatives NOVARTIS AG (CH) 2013-06-27 — — US disclosed
US-20130165436-A1 Dihydro-Benzo-Oxazine and Dihydro-Pyrido-Oxazine Derivatives NOVARTIS AG (CH) 2013-06-27 — — US disclosed
EP-2582698-A1 SUBSTITUTED 5-,6- AND 7-MEMBERED HETEROCYCLES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, AND THEIR USE Vitae Pharmaceuticals, Inc. (US) 2013-04-24 — — EP disclosed
WO-2011159760-A1 SUBSTITUTED 5-,6- AND 7-MEMBERED HETEROCYCLES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, AND THEIR USE VITAE PHARMACEUTICALS, INC. (US) 2011-12-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11931363-B2 Triazolopyrimidine compounds and uses thereof EZH2, DOT1L, EED KMT2A 27/4885MEN1 1351/4885NPC1 2908/4885
US-11207325-B2 Triazolopyrimidine compounds and uses thereof EZH2, DOT1L, EED KMT2A 27/4885MEN1 1351/4885NPC1 2908/4885
US-20130244993-A1 SUBSTITUTED 5-,6- AND 7-MEMBERED HETEROCYCLES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, AND THEIR USE CYP11B1, CYP11B2, HSD3B1 KMT2A 2511/4885MEN1 3015/4885NPC1 557/4885
US-20190233426-A1 IMIDAZOLEPYRIDINE COMPOUNDS AND USES THEREOF EZH2, DOT1L, BMI1 KMT2A 31/4885MEN1 630/4885NPC1 2483/4885
US-20200323859-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF EZH2, DOT1L, EED KMT2A 27/4885MEN1 1351/4885NPC1 2908/4885
US-10676479-B2 Imidazolepyridine compounds and uses thereof EZH2, DOT1L, BMI1 KMT2A 31/4885MEN1 630/4885NPC1 2483/4885
US-20130165436-A1 Dihydro-Benzo-Oxazine and Dihydro-Pyrido-Oxazine Derivatives PDXK, PDK1, DPYD KMT2A 3812/4885MEN1 4087/4885NPC1 3505/4885
US-20240216378-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF EZH2, DOT1L, EED KMT2A 27/4885MEN1 1351/4885NPC1 2908/4885
US-20190142837-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF EZH2, DOT1L, EED KMT2A 27/4885MEN1 1351/4885NPC1 2908/4885
US-20230033320-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF EZH2, DOT1L, EED KMT2A 27/4885MEN1 1351/4885NPC1 2908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.